Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Mahendra Kumar Trivedi, Shrikant Patil, Harish Shettigar, Khemraj Bairwa and Snehasis Jana
Shigella sonnei (S. sonnei) is a non-motile, rod shape, clinically significant, Gram-negative bacterium. It is commonly associated with dysentery (shigellosis). Recently, resistance to third and fourth generation cephalosporins and fluoroquinolones has been reported in S. sonnei. In the present study, we assessed the effect of biofield treatment on phenotyping and genotyping characteristic of S. sonnei (ATCC 9290). The lyophilized samples of S. sonnei were divided in three groups (G): G-I (control, revived), G-II (treatment, revived), and G-III (treatment, lyophilized). All these groups (control and biofield treated) were analyzed against antimicrobial susceptibility, biochemical reactions, and biotype number. The 16S rDNA sequencing was carried out to establish the phylogenetic relationship of S. sonnei with different bacterial species. The treated cells of S. sonnei exhibited an alteration of 3.33%, 10%, and 23.33% of total 30 tested antimicrobials in susceptibility assay for G-II on day 5 and 10 and G-III on day 10, respectively as compared to control. The treated cells of S. sonnei showed a significant change of about 12.12%, 12.12%, and 57.58% biochemical reactions out of 33 tests in treated groups of G-II on day 5 and 10 and G-III on day 10, respectively. The biotype number was also changed in treated samples of S. sonnei. Based on nucleotide homology sequences and phylogenetic analysis, the nearest homolog species of S. sonnei (GenBank Accession Number: EU009190) was identified as Shigella flexneri (EF643608). These results revealed that biofield treatment can prevent the absolute resistance in microbe against the existing antimicrobials.